NAD+ 500mg Information & Coordination for Licensed U.S. Clinics
Nicotinamide adenine dinucleotide, commonly referred to as NAD or NAD+, is a naturally occurring coenzyme involved in cellular metabolic processes.
The FDA lists Nicotinamide Adenine Dinucleotide (NAD) in Category 1 of its section 503A bulk-drug-substance framework, meaning the nominated substance remains under evaluation. Category 1 status is not FDA approval and does not mean the substance has been finally included on the 503A Bulks List.
The regulatory position under section 503B is different. In a January 2026 warning letter, the FDA stated that NAD+ used by GenoGenix LLC did not qualify for the relevant section 503B exemptions because it was not on the 503B Bulks List and was not being used to compound a drug on the FDA drug shortage list.
Phoenix Meds Inc. provides administrative and informational support concerning documentation and publicly available regulatory information for healthcare organizations.
We are not a pharmacy, medical practice, manufacturer, prescriber, compounder or dispensing entity.
NAD+ 500mg: What Clinics Should Know
NAD+ appears in wellness and longevity discussions, including discussions of injectable preparations.
Its biological role in cellular metabolism does not establish that an injectable preparation is an FDA-approved treatment for wellness, longevity, fatigue or cognitive concerns.
The regulatory framework matters. Section 503A and section 503B have separate requirements, and a substance’s appearance in an FDA nomination document does not, by itself, establish that a particular preparation qualifies for the relevant exemptions.
Readers should distinguish between the identity of a bulk substance, its status under an FDA evaluation framework, the particular preparation being discussed and the findings of any enforcement action involving a specific entity.
For other medications and more information explore our Medical Information page
503A and 503B Require Separate Review
The FDA maintains separate regulatory frameworks for traditional pharmacy compounding under section 503A and outsourcing facilities operating under section 503B of the Federal Food, Drug, and Cosmetic Act.
Section 503A: NAD+ Under Evaluation
The FDA’s section 503A document, updated May 14, 2026, lists Nicotinamide Adenine Dinucleotide (NAD) in Category 1, which covers nominated bulk drug substances under evaluation.
Category 1 is an evaluation status, not FDA approval or final inclusion on the 503A Bulks List. The FDA’s interim policy describes circumstances in which the agency does not intend to take enforcement action when its stated conditions are met. That policy should not be interpreted as blanket authorization for every preparation described commercially as NAD+.
Section 503B: A Different Regulatory Framework
The FDA’s section 503B nomination document, updated March 21, 2025, includes Beta-Nicotinamide Adenine Dinucleotide in Category 1 of the legacy framework for substances nominated before the January 2025 guidance. That historical listing does not establish the eligibility of every NAD+ preparation under section 503B.
In its January 20, 2026 warning letter to GenoGenix LLC, the FDA stated that the NAD+ products compounded by that facility did not qualify for the section 503B exemptions. The agency cited the absence of NAD+ from the 503B Bulks List and the fact that the products were not used to compound a drug appearing on the FDA drug shortage list. The letter also addressed the products’ ineligibility under the applicable interim policy.
This was a specific enforcement determination involving the facility and products described in that letter. It should not be replaced by a general assumption that every product marketed as NAD+ has the same regulatory status.
Sterile Compounding and Ingredient Quality
The FDA has specifically warned about food-grade NAD+ ingredients being used in preparations intended for sterile injection. Ingredients identified as food grade are not suitable for sterile drug compounding without appropriate processing because microbial contamination and excessive endotoxin levels can harm patients.
The FDA has received adverse-event reports following the use of injectable NAD+ products, including severe chills, shaking, vomiting and fatigue. Some patients required medical treatment. The agency noted that these reported reactions were consistent with excessive endotoxin exposure.
A separate FDA warning letter dated February 9, 2026, concerning Thrive Health and Wellness, LLC, described deficiencies in practices for producing drug products intended or expected to be sterile. The letter cited repackaged NAD+ 50 mg/mL among the products for which the firm did not have FDA-approved applications on file.
On July 27, 2026, the FDA issued a closeout letter stating that, based on its evaluation, the firm appeared to have adequately addressed the violations discussed in the warning letter. The closeout letter should be read alongside the original notice; it does not constitute FDA approval of a particular NAD+ product.
The Thrive letter concerned repackaged NAD+ 50 mg/mL, not a product identified as NAD+ 500 mg. It is an example of the FDA’s product-specific regulatory and sterile-processing concerns, not a finding about every preparation bearing a similar name.
Why Product Specific Documentation Matters
The description “NAD+ 500 mg” identifies a stated amount but does not establish the complete identity, concentration, dosage form, regulatory status, storage conditions, sterility assurance or suitability of a particular preparation.
Phoenix Meds Inc. should not publish universal product specifications on the basis of a strength label alone. This includes assumptions about:
- A standardized formulation or concentration.
- Routes of administration or fixed administration instructions.
- Refrigeration or other storage requirements.
- Lot-specific sterility, potency or endotoxin testing.
- Regulatory eligibility or FDA approval.
These are separate product-specific matters. Claims about them require appropriate supporting evidence from the responsible entity and must be assessed within the applicable regulatory framework.
How Phoenix Meds Supports Regulatory Understanding
Phoenix Meds Inc. provides administrative and informational support concerning documentation and publicly available regulatory information for healthcare organizations.
This support does not constitute FDA approval, pharmacy accreditation, laboratory testing, product authentication, clinical advice or a legal opinion. The information on this page does not certify any preparation’s identity, quality, sterility, safety or regulatory eligibility.
Questions concerning a particular product or compounding arrangement require review of the relevant facts by appropriately qualified healthcare and regulatory professionals.
Safety and Documentation Considerations
The FDA states that compounded drugs are not FDA-approved. They do not undergo the same premarket review for safety, effectiveness and quality as FDA-approved drugs. Poor compounding practices can result in contamination or incorrect amounts of active ingredients, potentially causing serious harm.
Facility registration should not be confused with product approval, and a general description of a substance does not establish that a particular preparation meets applicable requirements.
Phoenix Meds Inc. does not manufacture, compound, test, dispense, store, ship or take custody of NAD+ preparations. It does not certify a preparation’s purity, potency, sterility, endotoxin level, authenticity, safety or clinical suitability.
Understanding NAD+ Regulatory Information
Regulatory Listings
An FDA nomination or evaluation listing describes the status of a bulk drug substance within a specific framework. It should not be represented as FDA approval of a finished drug product.
Product-Specific Claims
Statements about concentration, formulation, storage, sterility or testing require evidence specific to the preparation being discussed. A stated strength alone cannot verify these characteristics.
Responsibilities of Licensed Professionals
Clinical decisions and regulated pharmaceutical activities remain the responsibility of appropriately qualified professionals and entities legally authorized to perform them. This page does not provide dosing instructions, administration protocols or treatment recommendations.
NAD+ 500mg Coordination for Licensed Clinics
If you are a licensed clinic seeking NAD+ 500 mg sourcing coordination, we will route your request to an appropriate licensed partner and help standardize the operational steps required to begin.
Clinic Verification
Professional and facility credentials may be reviewed as part of Phoenix’s administrative process.
Documentation Review
Phoenix may help organize available documentation and current regulatory information for review by the appropriate licensed professionals.
Pharmacy Fulfillment
Prescribing, compounding, dispensing, distribution, testing, storage, shipping, and other regulated pharmaceutical activities remain with the parties legally authorized and responsible for performing them.
Frequently Asked Questions
Is NAD+ 500 mg FDA-approved?
Compounded drug preparations are not FDA-approved. The regulatory status of a specific preparation depends on the applicable requirements and circumstances.
What should organizations know about NAD+ 500 mg regulatory status?
What administrative support does Phoenix Meds Inc. provide?
What documentation may be needed during coordination?
Does administrative coordination guarantee product quality or regulatory compliance?
How should product quality and sterility be assessed?
Quality and sterility should not be assumed from a product description alone. The relevant preparation, ingredients, source, and applicable quality requirements must be evaluated. The FDA has specifically raised concerns about unsuitable ingredients used in sterile compounding.
Where can organizations verify applicable requirements?
Organizations can consult official FDA drug-compounding guidance, applicable state requirements, and qualified regulatory advisers to clarify their responsibilities.
Important Notice
Phoenix Meds Inc. provides administrative coordination, documentation, and compliance-focused support for licensed healthcare organizations.
We are not a pharmacy, medical practice, manufacturer, outsourcing facility, compounder, prescriber, or dispensing entity.
This page is intended for professional informational purposes. It does not represent NAD+ as an FDA-approved treatment, establish clinical effectiveness for wellness or longevity uses, or establish that a particular preparation or compounding pathway is available or permitted.
Regulatory References
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B
- GenoGenix LLC Warning Letter, January 20, 2026
- Reminder to Use Ingredients Suitable for Sterile Compounding
- Thrive Health Solutions Warning Letter, February 9, 2026
- Thrive Health Solutions Closeout Letter, July 27, 2026
- Compounding and the FDA: Questions and Answers